Blanket Purchase Agreement 36F79722D0048-36E79722A0010
Award Date
1/15/22
Last Date to Order
9/14/24
Federal Agency
National Acquisition Center
Awardee
Eiger Biopharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
Eiger Biopharmaceuticals, Inc. holds a multiple-award Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) under the GSA Pharmaceuticals and Drugs schedule. This $225,000 contract allows Eiger to provide drugs, pharmaceuticals, and hematology-related products to VA medical facilities through January 2027. Under this FSS contract, the VA National Acquisition Center has awarded two single-award Blanket Purchase Agreements (BPAs) to Eiger. The first is a $204,359.25...
The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Eiger Biopharmaceuticals, Inc. for an estimated potential value of $205,000. No set-aside was used. The BPA is for the drug Zokinvy to treat progeroid laminopathies, a group of rare premature aging diseases. Eiger Biopharmaceuticals will supply Zokinvy to the VA through May 13, 2022 under the terms of this agreement. As the federal agency responsible for healthcare and benefits for...
BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, was awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The $151,685 BPA has a potential value over $3 million and will run through October 2024, facilitating the VA's procurement of the drug Palynziq (pegvaliase-pqpz) to treat phenylketonuria in adult patients. Under this BPA, the VA has issued a $117,376.50 firm...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the U.S. federal government, to Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit manufacturer of specialized pharmaceutical products. The BPA, valued at $131,039,520.00, is a single-award contract that falls under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule. It enables the procurement of various critical medications such as CINRYZE,...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide the drugs TEGSEDI and ORFADIN. The BPA, valued up to $11.75 million, covers the period from October 2021 through September 2025. Sobi, Inc. also holds a multiple award schedule contract with the VA valued at up to $78 million through July 2025 for pharmaceutical products under the Federal...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) to Regeneron Pharmaceuticals Inc., a for-profit pharmaceutical manufacturer. The BPA, which falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), has a ceiling value of $780,000.00 and an ultimate completion date of September 29, 2025. The primary product being procured under this BPA is the drug EVKEEZA. A firm fixed-price BPA Call Order was issued on November 24, 2021 with a...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Akebia Therapeutics, Inc. as a single-award contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA has a ceiling value of $10,254,764.65 and a period of performance from April 25, 2025 to April 24, 2026. The purpose of this BPA is to provide the VA with the pharmaceutical products VAFSEO and AURYXIA. No set-asides were used for this award....
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Genentech USA, Inc. for the procurement of Evrysdi. The BPA has a potential value of $1 million and a period of performance from March 12, 2021 through September 14, 2023, with four one-year option periods. The BPA was established against the Pharmaceuticals and Drugs GSA Schedule and provides a contracting vehicle for ordering Evrysdi to treat spinal muscular atrophy. Spinal muscular...